While our results support the combined use of bortezomib and COX-2 inhibitors for the treatment of MM [54], it is feasible for future MM research to investigate if the high COX2 MM phenotype might be potentiated by bortezomib itself. This evidence concerns the gene PTGS2 and Miyoshi myopathy.